JP2011503081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503081A5 JP2011503081A5 JP2010533163A JP2010533163A JP2011503081A5 JP 2011503081 A5 JP2011503081 A5 JP 2011503081A5 JP 2010533163 A JP2010533163 A JP 2010533163A JP 2010533163 A JP2010533163 A JP 2010533163A JP 2011503081 A5 JP2011503081 A5 JP 2011503081A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- inhibitor
- hydrogen
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 6
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229940125710 antiobesity agent Drugs 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 1
- 208000005676 Adrenogenital syndrome Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 206010013700 Drug hypersensitivity Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 201000011275 Epicondylitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004366 Glucosidases Human genes 0.000 claims 1
- 108010056771 Glucosidases Proteins 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010039792 Seborrhoea Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 102100038129 Transcription factor Dp family member 3 Human genes 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000004208 acquired thrombocytopenia Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 239000000464 adrenergic agent Substances 0.000 claims 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 claims 1
- 201000009614 adult lymphoma Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000028004 allergic respiratory disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940125709 anorectic agent Drugs 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 229940127003 anti-diabetic drug Drugs 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124605 anti-osteoporosis drug Drugs 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000002830 appetite depressant Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 201000004988 autoimmune vasculitis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000004709 chorioretinitis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125542 dual agonist Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000004526 exfoliative dermatitis Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000000147 hypnotic effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- -1 pyrrolidinyl Phenyl Chemical group 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 201000004335 respiratory allergy Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000007529 rheumatic myocarditis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 208000023924 subacute bursitis Diseases 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 201000006489 suppurative thyroiditis Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000005306 thianaphthenyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 102000004217 thyroid hormone receptors Human genes 0.000 claims 1
- 108090000721 thyroid hormone receptors Proteins 0.000 claims 1
- 239000000814 tuberculostatic agent Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98451507P | 2007-11-01 | 2007-11-01 | |
| PCT/US2008/081702 WO2009058944A2 (en) | 2007-11-01 | 2008-10-30 | Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503081A JP2011503081A (ja) | 2011-01-27 |
| JP2011503081A5 true JP2011503081A5 (enExample) | 2011-04-07 |
Family
ID=40289118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533163A Withdrawn JP2011503081A (ja) | 2007-11-01 | 2008-10-30 | グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8309730B2 (enExample) |
| EP (1) | EP2209780B1 (enExample) |
| JP (1) | JP2011503081A (enExample) |
| CN (1) | CN101910171A (enExample) |
| ES (1) | ES2448839T3 (enExample) |
| WO (1) | WO2009058944A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| EP2577290A1 (en) | 2010-06-07 | 2013-04-10 | Fritz-Lipmann-Institut e.V. Leibniz-Institut für Altersforschung | Agent against glucocorticoid-induced osteoporosis |
| AU2011293193A1 (en) * | 2010-08-27 | 2013-02-14 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| BR112014007124A2 (pt) * | 2011-11-17 | 2017-06-13 | Univ Indiana Res & Tech Corp | superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide |
| KR102352737B1 (ko) | 2013-11-25 | 2022-01-17 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 옥타하이드로 융합된 아자데칼린 글루코코르티코이드 수용체 조절제 |
| CN108864086A (zh) * | 2018-07-20 | 2018-11-23 | 新乡学院 | 一种四氢异喹啉并咪唑骨架化合物及其制备方法 |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CA3121193C (en) | 2018-12-19 | 2024-03-12 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| CA3131263C (en) | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| JP7569492B2 (ja) | 2019-12-11 | 2024-10-18 | コーセプト セラピューティクス， インコーポレイテッド | 抗精神病薬誘発性体重増加のミリコリラントによる治療方法 |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612114B2 (enExample) | 1974-06-07 | 1981-03-18 | ||
| US4046889A (en) | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
| NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
| US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| ATE60571T1 (de) | 1984-12-04 | 1991-02-15 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
| DE3543999A1 (de) | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
| US5100889A (en) | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5447954A (en) | 1992-05-05 | 1995-09-05 | Smithkline Beecham P.L.C. | Phenylderivate as inhibitors of ATP citrate lyase |
| US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
| SG45369A1 (en) | 1993-01-19 | 1998-10-16 | Warner Lambert Co | Stable oral ci-981 formulation and process of preparing same |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
| US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
| US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
| US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
| US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| ATE344279T1 (de) | 1995-12-13 | 2006-11-15 | Univ California | Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors |
| US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
| US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
| US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| JP2002506075A (ja) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | セリンペプチダーゼ調節剤 |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| WO2000038722A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| ATE496620T1 (de) | 2002-04-11 | 2011-02-15 | Merck Sharp & Dohme | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren |
| DE60331103D1 (de) | 2002-07-18 | 2010-03-11 | Bristol Myers Squibb Co | Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii |
| CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
-
2008
- 2008-10-30 CN CN2008801237144A patent/CN101910171A/zh active Pending
- 2008-10-30 JP JP2010533163A patent/JP2011503081A/ja not_active Withdrawn
- 2008-10-30 US US12/741,597 patent/US8309730B2/en active Active
- 2008-10-30 ES ES08843401.4T patent/ES2448839T3/es active Active
- 2008-10-30 WO PCT/US2008/081702 patent/WO2009058944A2/en not_active Ceased
- 2008-10-30 EP EP08843401.4A patent/EP2209780B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503081A5 (enExample) | ||
| KR101174201B1 (ko) | 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체 | |
| CA3125058C (en) | Fak inhibitor and drug combination thereof | |
| JP5671558B2 (ja) | フッソ含有重水素化ジフェニル尿素の製造方法 | |
| JP7397452B2 (ja) | ヘテロアリールカルボキシアミド化合物 | |
| RS61887B1 (sr) | Tetrahidropiranil amino-pirolopirimidinon i postupci njegove primene | |
| SG192439A1 (en) | Organic compounds | |
| PL151012B1 (en) | Method for manufacturing new n-benzoilurea compounds | |
| CA2737038A1 (en) | Amide compounds, compositions and uses thereof | |
| JP2020517677A5 (enExample) | ||
| KR20210005668A (ko) | Hpk1 억제제, 그의 제조 방법 및 응용 | |
| EP1976851A2 (en) | Phenoxy-substituted pyrimidines as adenosine receptor antagonists | |
| Bernard-Gauthier et al. | 5-(4-((4-[18F] fluorobenzyl) oxy)-3-methoxybenzyl) pyrimidine-2, 4-diamine: A selective dual inhibitor for potential PET imaging of Trk/CSF-1R | |
| Sun et al. | Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives | |
| TWI359017B (en) | Heteroaryl-hydrazone compounds | |
| CN103965133A (zh) | 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途 | |
| KR102220848B1 (ko) | 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형 | |
| JP6100755B2 (ja) | （２−ヘテロアリールアミノ）コハク酸誘導体 | |
| WO2017088755A1 (en) | Aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity | |
| TW200538098A (en) | Therapeutic agents | |
| JP2009541370A (ja) | 新規な尿素誘導体とその用途 | |
| US20140194452A1 (en) | Pyrazolyl-Based Carboxamides II | |
| EP3481810A1 (en) | Substituted aminothiazoles | |
| Chai et al. | Synthesis and acaricidal activity of strobilurin-pyrimidine derivatives | |
| CA3151407A1 (en) | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections |